CD8A and neoplasm: Interestingly, in B16 melanoma and H22 liver cancer tumor-bearing mouse models, CQ treatment promotes the antitumor immunity mediated by CD8+ T cells via activating the inflammatory cytokines, thereby causing TAMs to deviate from conversion of M2 phenotype to M1 phenotype (100).